3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

INVESTIGATING CELLULAR ANTIRETROVIRAL RESISTANCE: PRELIMINARY RESULTS OF THE "ICARE" STUDY

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. WeOa0201

Lafeuillade A.¹, Hittinger G.¹, Poggi C.², Benech H.³, Cupo A.^4
1 CHITS, Toulon, France, ² General Hospital, Toulon, France, ³ CEA, Gif sur Yvette, France, ⁴ CNRS, Sofia Antipolis, France

INTRODUCTION: Despite HAART, low levels of HIV-1 RNA remain detectable in blood and reservoirs of most patients. No in vivo data are currently available on antiretroviral diffusion in lymph node cells (LNMC) versus blood cells (PBMC), or their correlation with the expression of multi-drug resistance proteins (MDR).

METHODS: Ongoing study of patients on first-line effective HAART (plasma viremia <50 c/ml for >6 months). A blood sample and surgical lymph node biopsy are done simultaneously. HIV-1 RNA levels are measured using RT-PCR, intra-cellular levels of NRTI active metabolites are measured using LC/MS/MS or radio-immunology, PI levels in plasma and total lymph node tissue are measured with HPLC. mRNA expression of P-gp, MRP-4, MRP-5 in cells is measured by a semi-quantitative PCR.

RESULTS: 15 patients have already been analyzed, including 8 on Nelfinavir and 7 on Lopinavir- containing regimens. Four patients were also on tenofovir, 5 on abacavir, 7 on d4T, 8 on AZT and 11 on 3TC. Mean PBMC residual HIV RNA and DNA levels were respectively 44 and 2940 copies/million cells; mean LNMC residual HIV RNA and DNA levels were respectively 8420 and 5630 copies/million cells. Mean AZT-TP levels in PBMC were 4384 fmol/ million cells, 3TC-TP: 9.4 pmol/ million cells, d4T-TP: 66 fmol/ million cells, TDF-DP: 239 fmol/ million cells, CBV-TP: 2100 fmol/ million cells. AZT-TP levels were 10 fold lower in LNMC versus PBMC; 3TC-TP levels were 15 fold higher, d4T-TP, TDF-DP and CBV-TP were undetectable. The lymph node/plasma ratio was 58% for Nelfinavir and 21% for Lopinavir. High MDR mRNA expression was found in PBMC in 26% cases and in LNMC in 73% (p<0.03).

CONCLUSIONS: Huge differences in antiretroviral diffusion and metabolism are found in vivo in PBMC versus LNMC; these differences could be related to differences in MDR expression. These data may contribute to understanding the mechanisms of HIV-1 RNA persistence during effective.

Download PDF of this abstract.

050724
Clinical | WeOa0201 | Alain Lafeuillade
Pharmacological monitoring of ARV therapy

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.